Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts

Israeli generics giant Teva has agreed two deals to sell off a portfolio of women’s health products for a total of $1.4 billion (£1 billion) in cash.

Foundation Consumer Healthcare will buy four of Teva’s emergency contraception products for $675 million, while private equity firm CVC Capital Partners will take on medicines for contraception, fertility, menopause and osteoporosis for $703 million.

The deals follow Teva’s agreement earlier in September to sell off its intrauterine contraceptive device Paragard for $1.1 billion, and continues the company’s programme of selling off non-core businesses to raise money to pay off its debts. Teva has also stated it intends to sell off assets in its European cancer and pain relief businesses.

As Business editor, Phillip's aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping them abreast of trends and developments in the world of chemistry businesses.View full profile

More from Phillip Broadwith

Topics